RxDoctor Payments Data

Megan Wehri

Primary Care · van Wert, OHNPI 1255740643

Payments from drug & device makers

$887in general payments, 2019–2025

Across 51 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$245
  • Sunovion Pharmaceuticals Inc.$105
  • AstraZeneca$90
  • Abbott$60
  • Merck$48
  • GSK$46
  • plus $292 from 12 others

What the payments were for

  • Food & beverage$887100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$887 in reported general payments places this provider in the 65th percentile of 321 primary care providers in Ohio.

See all primary care providers in Ohio

Medicare billing

Part B allowed, 2024
$338
Medicare patients
16
Services billed
126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide71$69,582
OzempicSemaglutide45$47,971
JardianceEmpagliflozin45$32,126
FarxigaDapagliflozin Propanediol20$19,983
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr30$14,337
JanuviaSitagliptin Phosphate18$11,125
Breo ElliptaFluticasone/Vilanterol20$8,207
Incruse ElliptaUmeclidinium Bromide12$4,425
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$2,064
Novolog FlexpenInsulin Aspart15$2,031
Ultra-Fine Short Pen NeedlePen Needle, Diabetic14$1,229
Albuterol Sulfate HfaAlbuterol Sulfate40$1,022
Cyclobenzaprine Hcl78$867
Omeprazole95$817
Atorvastatin Calcium161$728

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$28$69,58271 claims
Novo NordiskOzempic$32$47,97145 claims
GSKAnoro Ellipta, Breo Ellipta, Incruse Ellipta$46$26,96862 claims
AstraZenecaFarxiga$90$19,98320 claims
MerckJanuvia$48$11,12518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 321 primary care providers in Ohio.

Other primary care in van Wert

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →